Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the effects of PV-10 in a clinically ...
GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ — Severe bacterial pneumonia remains a major cause of death in critically ill patients, largely due to impaired ...
Mayo Clinic researchers have developed a new method to identify which proteins are most likely to trigger an immune ...
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered ...
Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results